Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...

With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

Dexcom’s share price slid by as much as 40% after news that revenue was coming in below expectations—due in part to a realignment of its sales force ahead of Stelo’s launch, and its products ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

Dexcom CEO Kevin Sayer shared new data on the ... Most users signed up for subscriptions versus a one-time order. Stelo brought in $22 million in revenue in 2024, nearly $10 million less than ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform. Stelo, the first over-the-counter glucose biosensor ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans ... on the stock with a $100.00 price target. TipRanks tracks over ...

The flagship G7 and DexCom ONE+ platforms continued to drive adoption internationally, with launches in key regions such as France, Australia and Japan bolstering growth. Early success with the newly ...